麒盛科技(603610.SH):美國4月3日公佈的關稅政策暫未對公司主力產品線及主要客戶訂單產生實質性影響
格隆匯4月8日丨麒盛科技(603610.SH)在互動平臺表示,2023年度,公司對美出口比例約爲79.38%,並通過全球化產能佈局有效管控潛在風險。目前,公司已構建中國智能製造基地與越南、墨西哥組裝工廠協同發展的柔性供應鏈體系,實現對美國市場的靈活供給。在越南,公司智能電動牀產品屬於美國232關稅清單中的豁免品類,可免於徵收對等關稅;在墨西哥,通過少量工序的本地化調整,智能電動牀產品符合USMCA協議政策,從而得到關稅豁免。公司積極與客戶保持溝通,根據最新業務評估,美國4月3日公佈的關稅政策暫未對公司主力產品線及主要客戶訂單產生實質性影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.